Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203707 | 0.82 | LMNA (0.46) | RAB9ASMN1; SMN2NPC1KMT2AHPGD | |
| SCHEMBL6617429 | 0.81 | ALDH1A1 (0.40) | RAB9ASMN1; SMN2NPC1KMT2AGAA | |
| SCHEMBL956476 | 0.76 | ALDH1A1 (0.43) | RAB9ASMN1; SMN2NPC1KMT2ALMNA | |
| SCHEMBL1202080 | 0.75 | KDM4E (0.52) | RAB9ASMN1; SMN2NPC1KMT2AMAPT | |
| SCHEMBL1203470 | 0.74 | KCNQ3 (0.46) | RAB9ASMN1; SMN2NPC1EPHB3 | |
| SCHEMBL953671 | 0.72 | MAPK1 (0.52) | RAB9ASMN1; SMN2NPC1KMT2AHPGD | |
| SCHEMBL954064 | 0.71 | ALDH1A1 (0.39) | RAB9ASMN1; SMN2NPC1KMT2ALMNA | |
| SCHEMBL19723607 | 0.70 | SMN1; SMN2 (0.70) | RAB9ASMN1; SMN2NPC1KMT2ALMNA | |
| SCHEMBL15562881 | 0.70 | MEN1 (0.38) | RAB9ASMN1; SMN2NPC1KMT2ALMNA | |
| SCHEMBL13325556 | 0.69 | SMN1; SMN2 (0.43) | RAB9ASMN1; SMN2NPC1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2217601-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | RAB9A 2147/4885SMN1; SMN2 4097/4885NPC1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.